Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06113471 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 69 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. 3 versions Re-verified since Jan 30, 2026, no change to tracked fieldsv67-v69
  2. Primary completion date: May 18, 2026 to Mar 17, 2026 Completion date: May 17, 2027 to Mar 16, 2027v66 Show 1 more changeShow less
    • Completion date: May 17, 2027 to Mar 16, 2027
  3. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 444 to confirmed 450 · Study sites: 92 to 86v65 Show 2 more changesShow less
    • Enrollment target: estimated 444 to confirmed 450
    • Study sites: 92 to 86
  4. Study sites: 90 to 92v64
  5. Study sites: 92 to 90v63
Show 43 earlier versionsHide 43 earlier versions
  1. Study sites: 90 to 92v62
  2. Study sites: 92 to 90v61
  3. Study sites: 93 to 92v60
  4. Study sites: 89 to 93v59
  5. Study sites: 93 to 89v58
  6. Study sites: 89 to 93v57
  7. Study sites: 93 to 89v56
  8. Study sites: 89 to 93v55
  9. Study sites: 93 to 89v54
  10. Study sites: 89 to 93v53
  11. Study sites: 93 to 89v52
  12. Study sites: 89 to 93v51
  13. Study sites: 93 to 89v50
  14. Study sites: 89 to 93v49
  15. Study sites: 93 to 89v48
  16. Study sites: 89 to 93v47
  17. Study sites: 93 to 89v46
  18. Study sites: 89 to 93v45
  19. Study sites: 93 to 89v44
  20. Study sites: 88 to 93v43
  21. Study sites: 92 to 88v42
  22. Study sites: 88 to 92v41
  23. Study sites: 92 to 88v40
  24. Study sites: 87 to 92v39
  25. Study sites: 90 to 87v38
  26. Study sites: 86 to 90v37
  27. Study sites: 90 to 86v36
  28. Study sites: 86 to 90v35
  29. Study sites: 90 to 86v34
  30. Study sites: 86 to 90v33
  31. Study sites: 90 to 86v32
  32. Site details revised at 5 of 90 sitesv31
  33. Study sites: 86 to 90v30
  34. Study sites: 90 to 86v29
  35. Study sites: 86 to 90v28
  36. Study sites: 90 to 86v27
  37. Study sites: 86 to 90v26
  38. Site details revised at 5 of 86 sitesv25
  39. Study sites: 90 to 86v24
  40. Study sites: 86 to 90v23
  41. Study sites: 90 to 86v22
  42. Study sites: 86 to 90v21
  43. Study sites: 90 to 86v20
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incyte
94 trials monitored
See 9 trials at risk
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Trial Details
NCT Number NCT06113471
Lead Sponsor Incyte Corporation
Conditions NonSegmental Vitiligo
Enrollment 450 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov